Cargando…

Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered From Stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials

Hypertension is the most important risk factor for stroke and stroke recurrence. However, the preferred blood pressure (BP)-lowering drug class for patients who have suffered from a stroke has yet to be determined. To investigate the relative effects of BP-lowering therapies [angiotensin-converting...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei-Ting, You, Li-Kai, Chiang, Chern-En, Sung, Shih-Hsien, Chuang, Shao-Yuan, Cheng, Hao-Min, Chen, Chen-Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839815/
https://www.ncbi.nlm.nih.gov/pubmed/27082571
http://dx.doi.org/10.1097/MD.0000000000003302
_version_ 1782428193262665728
author Wang, Wei-Ting
You, Li-Kai
Chiang, Chern-En
Sung, Shih-Hsien
Chuang, Shao-Yuan
Cheng, Hao-Min
Chen, Chen-Huan
author_facet Wang, Wei-Ting
You, Li-Kai
Chiang, Chern-En
Sung, Shih-Hsien
Chuang, Shao-Yuan
Cheng, Hao-Min
Chen, Chen-Huan
author_sort Wang, Wei-Ting
collection PubMed
description Hypertension is the most important risk factor for stroke and stroke recurrence. However, the preferred blood pressure (BP)-lowering drug class for patients who have suffered from a stroke has yet to be determined. To investigate the relative effects of BP-lowering therapies [angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blockers (ARB), β blockers, calcium channel blockers (CCBs), diuretics, and combinations of these drugs] in patients with a prior stroke history, we performed a systematic review and meta-analysis using both traditional frequentist and Bayesian random-effects models and meta-regression of randomized controlled trials (RCTs) on the outcomes of recurrent stroke, coronary heart disease (CHD), and any major adverse cardiac and cerebrovascular events (MACCE). Trials were identified from searches of published hypertension guidelines, electronic databases, and previous systematic reviews. Fifteen RCTs composed of 39,329 participants with previous stroke were identified. Compared with the placebo, only ACEI along with diuretics significantly reduced recurrent stroke events [odds ratio (OR) = 0.54, 95% credibility interval (95% CI) 0.33–0.90]. On the basis of the distribution of posterior probabilities, the treatment ranking consistently identified ACEI along with diuretics as the preferred BP-lowering strategy for the reduction of recurrent stroke and CHD (31% and 35%, respectively). For preventing MACCE, diuretics appeared to be the preferred agent for stroke survivors (34%). Moreover, the meta-regression analysis failed to demonstrate a statistical significance between BP reduction and all outcomes (P = 0.1618 for total stroke, 0.4933 for CHD, and 0.2411 for MACCE). Evidence from RCTs supports the use of diuretics-based treatment, especially when combined with ACEI, for the secondary prevention of recurrent stroke and any vascular events in patients who have suffered from stroke.
format Online
Article
Text
id pubmed-4839815
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-48398152016-06-02 Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered From Stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials Wang, Wei-Ting You, Li-Kai Chiang, Chern-En Sung, Shih-Hsien Chuang, Shao-Yuan Cheng, Hao-Min Chen, Chen-Huan Medicine (Baltimore) 3400 Hypertension is the most important risk factor for stroke and stroke recurrence. However, the preferred blood pressure (BP)-lowering drug class for patients who have suffered from a stroke has yet to be determined. To investigate the relative effects of BP-lowering therapies [angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blockers (ARB), β blockers, calcium channel blockers (CCBs), diuretics, and combinations of these drugs] in patients with a prior stroke history, we performed a systematic review and meta-analysis using both traditional frequentist and Bayesian random-effects models and meta-regression of randomized controlled trials (RCTs) on the outcomes of recurrent stroke, coronary heart disease (CHD), and any major adverse cardiac and cerebrovascular events (MACCE). Trials were identified from searches of published hypertension guidelines, electronic databases, and previous systematic reviews. Fifteen RCTs composed of 39,329 participants with previous stroke were identified. Compared with the placebo, only ACEI along with diuretics significantly reduced recurrent stroke events [odds ratio (OR) = 0.54, 95% credibility interval (95% CI) 0.33–0.90]. On the basis of the distribution of posterior probabilities, the treatment ranking consistently identified ACEI along with diuretics as the preferred BP-lowering strategy for the reduction of recurrent stroke and CHD (31% and 35%, respectively). For preventing MACCE, diuretics appeared to be the preferred agent for stroke survivors (34%). Moreover, the meta-regression analysis failed to demonstrate a statistical significance between BP reduction and all outcomes (P = 0.1618 for total stroke, 0.4933 for CHD, and 0.2411 for MACCE). Evidence from RCTs supports the use of diuretics-based treatment, especially when combined with ACEI, for the secondary prevention of recurrent stroke and any vascular events in patients who have suffered from stroke. Wolters Kluwer Health 2016-04-18 /pmc/articles/PMC4839815/ /pubmed/27082571 http://dx.doi.org/10.1097/MD.0000000000003302 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle 3400
Wang, Wei-Ting
You, Li-Kai
Chiang, Chern-En
Sung, Shih-Hsien
Chuang, Shao-Yuan
Cheng, Hao-Min
Chen, Chen-Huan
Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered From Stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials
title Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered From Stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials
title_full Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered From Stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials
title_fullStr Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered From Stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials
title_full_unstemmed Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered From Stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials
title_short Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have Already Suffered From Stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials
title_sort comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke: traditional and bayesian network meta-analysis of randomized trials
topic 3400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839815/
https://www.ncbi.nlm.nih.gov/pubmed/27082571
http://dx.doi.org/10.1097/MD.0000000000003302
work_keys_str_mv AT wangweiting comparativeeffectivenessofbloodpressureloweringdrugsinpatientswhohavealreadysufferedfromstroketraditionalandbayesiannetworkmetaanalysisofrandomizedtrials
AT youlikai comparativeeffectivenessofbloodpressureloweringdrugsinpatientswhohavealreadysufferedfromstroketraditionalandbayesiannetworkmetaanalysisofrandomizedtrials
AT chiangchernen comparativeeffectivenessofbloodpressureloweringdrugsinpatientswhohavealreadysufferedfromstroketraditionalandbayesiannetworkmetaanalysisofrandomizedtrials
AT sungshihhsien comparativeeffectivenessofbloodpressureloweringdrugsinpatientswhohavealreadysufferedfromstroketraditionalandbayesiannetworkmetaanalysisofrandomizedtrials
AT chuangshaoyuan comparativeeffectivenessofbloodpressureloweringdrugsinpatientswhohavealreadysufferedfromstroketraditionalandbayesiannetworkmetaanalysisofrandomizedtrials
AT chenghaomin comparativeeffectivenessofbloodpressureloweringdrugsinpatientswhohavealreadysufferedfromstroketraditionalandbayesiannetworkmetaanalysisofrandomizedtrials
AT chenchenhuan comparativeeffectivenessofbloodpressureloweringdrugsinpatientswhohavealreadysufferedfromstroketraditionalandbayesiannetworkmetaanalysisofrandomizedtrials